1. Home
  2. CERO vs LCFY Comparison

CERO vs LCFY Comparison

Compare CERO & LCFY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CERO
  • LCFY
  • Stock Information
  • Founded
  • CERO 2017
  • LCFY 2009
  • Country
  • CERO United States
  • LCFY Australia
  • Employees
  • CERO N/A
  • LCFY N/A
  • Industry
  • CERO
  • LCFY
  • Sector
  • CERO
  • LCFY
  • Exchange
  • CERO Nasdaq
  • LCFY Nasdaq
  • Market Cap
  • CERO 8.4M
  • LCFY 9.9M
  • IPO Year
  • CERO N/A
  • LCFY 2022
  • Fundamental
  • Price
  • CERO $1.79
  • LCFY $8.40
  • Analyst Decision
  • CERO
  • LCFY
  • Analyst Count
  • CERO 0
  • LCFY 0
  • Target Price
  • CERO N/A
  • LCFY N/A
  • AVG Volume (30 Days)
  • CERO 745.6K
  • LCFY 18.2K
  • Earning Date
  • CERO 03-04-2025
  • LCFY 04-01-2025
  • Dividend Yield
  • CERO N/A
  • LCFY N/A
  • EPS Growth
  • CERO N/A
  • LCFY N/A
  • EPS
  • CERO N/A
  • LCFY N/A
  • Revenue
  • CERO N/A
  • LCFY $2,668,385.00
  • Revenue This Year
  • CERO N/A
  • LCFY N/A
  • Revenue Next Year
  • CERO N/A
  • LCFY N/A
  • P/E Ratio
  • CERO N/A
  • LCFY N/A
  • Revenue Growth
  • CERO N/A
  • LCFY N/A
  • 52 Week Low
  • CERO $1.57
  • LCFY $2.20
  • 52 Week High
  • CERO $1,095.00
  • LCFY $11.23
  • Technical
  • Relative Strength Index (RSI)
  • CERO 36.41
  • LCFY 57.38
  • Support Level
  • CERO $1.70
  • LCFY $5.80
  • Resistance Level
  • CERO $2.10
  • LCFY $8.95
  • Average True Range (ATR)
  • CERO 0.23
  • LCFY 0.63
  • MACD
  • CERO 0.23
  • LCFY 0.13
  • Stochastic Oscillator
  • CERO 33.85
  • LCFY 82.54

About CERO CERo Therapeutics Holdings Inc. Common Stock

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

About LCFY Locafy Limited

Locafy Ltd is focused on commercializing its Software as a Service (SaaS) online publishing technology platform. Its platform enables the ability to publish almost any type of content to almost any device that uses a web browser to display web content. The firm has two operating segments: Publishing and SEO agency. Under the Publishing segment are products and services that the Company offers that are related to digital properties (i.e. mastheads) that it owns e.g. business data published on Hotfrog, advertising placed on AussieWeb, articles published on scoop.com.au. In contrast, under the SEO Agency segment are products and services that are applied to digital properties that are owned and operated by third parties. It derives a majority of its revenue in North America from SEO Agency.

Share on Social Networks: